Related Experiment Video
Updated: Jan 17, 2026
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
Genomic Newborn Screening: Commodity or Public Good?
Christopher Gyngell1,2, Sebastian Lunke1,2, Danya Vears1,3
1Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Insights
Genomic newborn screening (gNBS) offers broad genetic condition detection but faces implementation hurdles. Fee-for-service models risk inequity, necessitating research for equitable public healthcare integration.
Area of Science:
- Genomics
- Public Health
- Bioethics
Background:
- Genomic newborn screening (gNBS) has the potential to identify numerous genetic conditions early.
- Current public health programs do not widely offer gNBS due to insufficient evidence and implementation challenges.
Purpose of the Study:
- To discuss the ethical and practical implications of offering gNBS as a fee-for-service option before public funding decisions.
- To explore the risks of inequitable access and fragmented care associated with private gNBS offerings.
Main Methods:
- Ethical and policy analysis of fee-for-service genomic newborn screening.
- Discussion of potential risks and mitigation strategies for private gNBS implementation.
Main Results:
- Fee-for-service gNBS may create healthcare inequities and data control issues.
- Regulated private offerings through public genomics services could potentially reduce some risks.
Conclusions:
- Equitable access to gNBS is a significant concern with fee-for-service models.
- Further large-scale research is crucial for developing and implementing gNBS equitably within public healthcare systems.
Abstract:
Genomic newborn screening (gNBS) can screen for a broad range of genetic conditions, potentially enabling early treatment and improving health outcomes. However, it remains outside publicly funded programmes due to limited evidence and substantial implementation challenges. Offering gNBS in the interim as a fee-for-service option in Australia risks creating inequitable healthcare access, fragmenting care and limiting control over genomic data. Conversely, prohibiting private access may unfairly deny potential benefits to individual infants and families. This article discusses the ethical and practical implications of offering gNBS on a fee-for-service basis prior to a decision being made regarding public funding. Although fee-for-service gNBS undermines equitable access, regulated private offerings by public genomics services could mitigate some of the risks. We emphasise the need for large-scale, well-designed research studies to inform the development and equitable implementation of robust gNBS programmes within public healthcare frameworks.
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
03:00Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
02:02Genomics
01:59CRISPR
01:29Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
00:49What is Genetic Engineering?